Aptamer-drug conjugation for targeted tumor cell therapy

Michael J Donovan; Ling Meng; Tao Chen; Yunfei Zhang; Kwame Sefah; Weihong Tan

doi:10.1007/978-1-61779-188-8_9

Aptamer-drug conjugation for targeted tumor cell therapy

Methods Mol Biol. 2011:764:141-52. doi: 10.1007/978-1-61779-188-8_9.

Authors

Michael J Donovan¹, Ling Meng, Tao Chen, Yunfei Zhang, Kwame Sefah, Weihong Tan

Affiliation

¹ Department of Chemistry, Shands Cancer Center, Moffitt Cancer Center, Center for Research at Bio/Nano Interface, UF Genetics Institute and McKnight Brain Institute, University of Florida, Gainesville, FL, USA. mjdonovan@ufl.edu

PMID: 21748638
DOI: 10.1007/978-1-61779-188-8_9

Abstract

Aptamers developed for applications in cancer therapy can improve the efficacy of drug treatment and enhance molecular imaging. Aptamers for these purposes are generated from SELEX (Systematic Evolution of Ligands by EXponential enrichment), more precisely cell-based SELEX, a process described in detail in this chapter. Experimental applications are also provided for aptamer-based drugs.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antineoplastic Agents / chemistry*
Antineoplastic Agents / metabolism
Antineoplastic Agents / pharmacology
Aptamers, Nucleotide / chemistry*
Aptamers, Nucleotide / metabolism
Aptamers, Nucleotide / pharmacology
Biotin / metabolism
Cell Line, Tumor
Doxorubicin / chemistry*
Doxorubicin / metabolism
Doxorubicin / pharmacology
Humans
Leukemia / drug therapy*
Leukemia / pathology
Ligands
Molecular Targeted Therapy / methods*
SELEX Aptamer Technique / methods*
Streptavidin / metabolism

Substances

Antineoplastic Agents
Aptamers, Nucleotide
Ligands
Biotin
Doxorubicin
Streptavidin